"Just Attach It to Treat Heart Failure"... World’s First Transplant of Cardiac Muscle Sheet Made from Stem Cells in Japan
Man in His 50s With Severe Heart Failure Receives First Ever iPS Cell Transplant
Japan has become the first country in the world to perform surgery transplanting induced pluripotent stem cells (iPS cells). This marks the first time a regenerative medicine product made using iPS cells has been implanted in a patient and actually used for clinical treatment.
On September 30, the Asahi Shimbun reported that on the previous day, medical staff at Osaka Police Hospital in Osaka Prefecture had successfully transplanted "Reheart," a regenerative medicine product made from iPS cells for treating heart failure, into a patient in his 50s suffering from severe heart failure.
Japanese Quar Lips made a mini heart using iPS cells. It was created to help understand the principle of 'Rehart,' a heart muscle sheet, and was exhibited last year at the Osaka-Kansai Expo. Quar Lips.
View original imageiPS cells are somatic cells, such as skin cells, that have completed differentiation, but are engineered to acquire stem cell properties by introducing certain genes. These cells are then induced to differentiate into various types of bodily tissue. This technology was first developed in 2006 by Shinya Yamanaka of Kyoto University, who was subsequently awarded the Nobel Prize in Physiology or Medicine in 2012 for this achievement.
Among such products, Reheart is a "cardiac muscle sheet" in which iPS cells are transformed into cardiomyocytes and formed into a sheet. Quarips, a startup from Osaka University, developed this product. When the sheet is attached to the patient’s heart, it releases substances that help regenerate blood vessels, thereby improving physical stamina and cardiac function. As a result, it is being noted as a new treatment option for patients with severe heart failure whose cardiac function is significantly impaired.
According to the Asahi Shimbun, the recipient of the transplant is a resident of Kanagawa Prefecture who, in 2022, was transported to the hospital by ambulance due to breathing difficulties while outside and was diagnosed with severe heart failure caused by myocardial infarction. His symptoms worsened to the point where he was unable to walk or climb stairs. Although medication was continued, the medical staff ultimately determined that “no further treatment could be provided.” For this reason, the patient had consistently hoped to receive the new cardiac muscle sheet therapy. The operation was successful, and the Asahi Shimbun reported that the patient is expected to be discharged within two weeks to a month.
Reheart received manufacturing and sales approval in March this year under Japan’s “conditional and time-limited approval system.” Starting this month, it has also been covered by the national health insurance plan, and thus this surgery was also covered. This system allows the conditional use of regenerative medicine products for a set period so they can be supplied swiftly to patients, and then re-verifies their efficacy and safety based on actual clinical data.
As Reheart is still under conditional approval, Quarips must demonstrate its therapeutic effectiveness and safety by implanting Reheart in a total of 75 patients at multiple medical institutions within the next seven years. According to the Asahi Shimbun, a previous clinical trial with eight patients showed an improvement in symptoms such as shortness of breath during daily life within one year after transplantation. Of these, four patients also showed improved physical function.
However, the high cost of treatment remains a challenge. The price of Reheart is 53.2 million yen (about 459.46 million won), which is extremely expensive compared to standard pharmaceuticals. Although Japan’s high-cost medical care support system can reduce the patient’s out-of-pocket expense to several hundred thousand yen, the bulk of the cost must still be covered by public health insurance. As such, debates about the cost-effectiveness of the treatment are expected to continue, according to the Asahi Shimbun.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Other therapies using iPS cells are also being commercialized in Japan. "Amcefree," an iPS cell treatment for Parkinson’s disease developed by Sumitomo Pharma, is also expected to be available for patient treatment as early as next month.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.